LONDON (Reuters) Sept 21 - Novartis AG's experimental leukaemia drug Tasigna -- a follow-up to Glivec/Gleevec -- has been recommended for approval in Europe for patients who no longer respond to Glivec.
Tasigna works in about half of those patients who develop resistance to Glivec, the market-leading drug for the most common type of chronic myeloid leukaemia, or CML.
Bristol-Myers Squibb's rival product, Sprycel, is designed to treat the same group of patients.
The European Medicines Agency also said on Friday it had backed a new product, called Eucreas, combining the Swiss group's Galvus (vildagliptin) with metformin as a treatment for diabetes. Eucreas will be the first single-tablet combination of a DPP-4 inhibitor drug and metformin in Europe.
Galvus itself won a positive recommendation in Europe in July and may be formally approved by European authorities later this month or in October.
Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
Galvus's path to market in the key U.S. market has been delayed by worries over skin toxicity.
No comments:
Post a Comment